Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

713 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recent Advances in Desmoid Tumor Therapy.
Napolitano A, Mazzocca A, Spalato Ceruso M, Minelli A, Baldo F, Badalamenti G, Silletta M, Santini D, Tonini G, Incorvaia L, Vincenzi B. Napolitano A, et al. Cancers (Basel). 2020 Aug 1;12(8):2135. doi: 10.3390/cancers12082135. Cancers (Basel). 2020. PMID: 32752153 Free PMC article. Review.
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.
Vincenzi B, Galluzzo S, Santini D, Rocci L, Loupakis F, Correale P, Addeo R, Zoccoli A, Napolitano A, Graziano F, Ruzzo A, Falcone A, Francini G, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: napolitano a. Ann Oncol. 2011 May;22(5):1141-1146. doi: 10.1093/annonc/mdq550. Epub 2010 Nov 29. Ann Oncol. 2011. PMID: 21115601 Free article.
Evidence-based guidelines: Improving AGREEment on consistence evaluation.
Vincenzi B, Napolitano A, Santini D, Maiello E, Torri V, Tonini G. Vincenzi B, et al. Among authors: napolitano a. J Bone Oncol. 2012 Apr 30;1(1):30-4. doi: 10.1016/j.jbo.2012.04.001. eCollection 2012 Jun. J Bone Oncol. 2012. PMID: 26909252 Free PMC article.
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Vincenzi B, et al. Among authors: napolitano a. Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30181783 Free PMC article.
713 results